

June 17, 2019
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights
 (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment**

TOKYO, Japan, June 17, 2019—Symbio Pharmaceuticals Limited (JASDAQ: 4582) announces the monthly exercise status and the large volume exercise of the 46th Stock Acquisition Rights issued during the period from June 14, 2019 to June 17, 2019, and that the exercise of all 46th stock acquisition rights issued and allotted to EVO FUND on April 25, 2018, are completed as of today.

I. The Large Volume Exercise

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 46 th Stock Acquisition Rights
(2)	Number of issued shares from the previous disclosure	1,866,000 Shares
(3)	Number of stock acquisition rights being exercised from the previous disclosure and the ratio to the entire issue	1,866,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 12.44%)
(4)	Number of unexercised stock acquisition rights as of the previous disclosure	1,866,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	0 Units

(6) Exercise status from the previous disclosure

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
June 14 (Fri.)	—	—	154	—
June 17 (Mon.)	1,866,000	—	154	1,866,000

※Number of issued shares at the end of the previous month : 91,784,724 shares [of which 75 shares are treasury shares]

II. Monthly Exercise Status

(1)	Name of the stock acquisition rights	SymBio Pharmaceuticals Limited 46 th Stock Acquisition Rights
(2)	Number of issued shares from the beginning of the month	5,666,000 Shares
(3)	Number of stock acquisition rights being exercised from the beginning of the month and the ratio to the entire issue	5,666,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 37.77%)
(4)	Number of unexercised stock acquisition rights as of the beginning of the month	5,666,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	0 Units

(6) Exercise status from the beginning of the month

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
June 3 (Mon.)	—	—	165	—
June 4 (Tue.)	500,000	—	162	500,000
June 5 (Wed.) to June 10 (Mon.)	—	—	162	—
June 11 (Tue.)	1,800,000	—	154	1,800,000
June 12 (Wed.)	500,000	—	154	500,000
June 13 (Thu.)	1,000,000	—	154	1,000,000
June 14 (Fri.)	—	—	154	—
June 17 (Mon.)	1,866,000	—	154	1,866,000

※Number of issued shares at the end of the previous month : 91,784,724 shares [of which 75 shares are treasury shares]

(7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)

① Total number of shares delivered upon the exercise of all series of stock acquisition rights	② Number of listed shares at the time of the payment for the issuance	③ Exercise ratio on exercise limit(①/②)
5,666,000 Shares	57,840,724Shares	9.80%

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.